ATE507830T1 - Verwendung von antagonisten von oxytocin und/oder vasopressin bei der assistierten fortpflanzung - Google Patents

Verwendung von antagonisten von oxytocin und/oder vasopressin bei der assistierten fortpflanzung

Info

Publication number: ATE507830T1
Authority: AT; Austria
Prior art keywords: oxytocin; antagonists; vasopressin; medicament; manufacture
Prior art date: 2005-05-10

Application number

AT06747719T

Other languages

English (en)

Inventor

Waldemar Kuczynski

Piotr Pierzynski

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-10

Filing date

2006-05-10

Publication date

2011-05-15

2005-05-10 Priority claimed from PL374954A external-priority patent/PL374954A1/pl

2005-08-12 Priority claimed from PL376607A external-priority patent/PL376607A1/pl

2006-05-10 Application filed by Ferring Bv filed Critical Ferring Bv

2011-05-15 Application granted granted Critical

2011-05-15 Publication of ATE507830T1 publication Critical patent/ATE507830T1/de

Links

XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 4
239000005557 antagonist Substances 0.000 title abstract 4
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 4
229960001723 oxytocin Drugs 0.000 title abstract 4
101800000989 Oxytocin Proteins 0.000 title abstract 3
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 3
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title abstract 3
108010004977 Vasopressins Proteins 0.000 title abstract 3
102000002852 Vasopressins Human genes 0.000 title abstract 3
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title abstract 3
229960003726 vasopressin Drugs 0.000 title abstract 3
239000003814 drug Substances 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
102000004279 Oxytocin receptors Human genes 0.000 abstract 1
108090000876 Oxytocin receptors Proteins 0.000 abstract 1
102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
230000037020 contractile activity Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000009027 insemination Effects 0.000 abstract 1
210000001161 mammalian embryo Anatomy 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
210000004291 uterus Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT06747719T 2005-05-10 2006-05-10 Verwendung von antagonisten von oxytocin und/oder vasopressin bei der assistierten fortpflanzung ATE507830T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
PL374954A PL374954A1 (pl)	2005-05-10	2005-05-10	Zastosowanie antagonistów oksytocyny lub antagonistów oksytocyny i wazopresyny lub antagonistów wazopresyny do wytwarzania leków stosowanych podczas procedur wspomaganego rozrodu
PL376607A PL376607A1 (pl)	2005-08-12	2005-08-12	Zastosowanie antagonistów oksytocyny i/lub wazopresyny
US73391605P	2005-11-04	2005-11-04
PCT/PL2006/000029 WO2006121362A2 (en)	2005-05-10	2006-05-10	Use of antagonists of oxytocin and/or vasopressin in assisted reproduction

Publications (1)

Publication Number	Publication Date
ATE507830T1 true ATE507830T1 (de)	2011-05-15

Family

ID=37056586

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06747719T ATE507830T1 (de)	2005-05-10	2006-05-10	Verwendung von antagonisten von oxytocin und/oder vasopressin bei der assistierten fortpflanzung

Country Status (20)

Country	Link
US (1)	US20080318847A1 (de)
EP (1)	EP1879572B1 (de)
JP (1)	JP4762308B2 (de)
KR (1)	KR100985449B1 (de)
CN (1)	CN101646436B (de)
AT (1)	ATE507830T1 (de)
AU (1)	AU2006244693B2 (de)
CA (1)	CA2605923C (de)
DE (1)	DE602006021736D1 (de)
DK (1)	DK1879572T3 (de)
ES (1)	ES2366130T3 (de)
IL (1)	IL186595A (de)
MX (1)	MX2007014022A (de)
NO (1)	NO340956B1 (de)
NZ (1)	NZ562409A (de)
PL (1)	PL1879572T3 (de)
PT (1)	PT1879572E (de)
RU (1)	RU2385735C2 (de)
SI (1)	SI1879572T1 (de)
WO (1)	WO2006121362A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103417475B (zh) *	2013-06-27	2015-06-17	深圳翰宇药业股份有限公司	一种巴鲁西班注射液及其制备方法
EP2845850A1 (de)	2013-09-10	2015-03-11	ObsEva S.A.	Pyrrolidinderivate als Oxytocin/Vasopressin-V1a-Rezeptorantagonisten
EP2886107A1 (de) *	2013-12-17	2015-06-24	ObsEva S.A.	Orale Formulierungen von Pyrrolydinderivaten
EP3753921A1 (de)	2014-07-02	2020-12-23	ObsEva S.A.	Kristallines (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-on-o-methyloxim und verfahren zur verwendung davon
EP3037101B1 (de) *	2014-12-22	2019-03-06	Ferring B.V.	Oxytocinrezeptorantagonistentherapie in der Lutealphase für Implantation und Schwangerschaft bei mit Technologien zur unterstützten Fortpflanzung behandelten Frauen
UA127283C2 (uk) *	2016-07-21	2023-07-12	Обсева С.А.	Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню
US20220323410A1 (en) *	2019-09-03	2022-10-13	ObsEva S.A.	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20220395511A1 (en) *	2021-06-10	2022-12-15	Washington University	Compositions and methods for increasing cell surface oxytocin receptor (oxtr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US962413A (en) *	1909-05-13	1910-06-28	George Hillard Benjamin	Method of soldering chains.
US5948762A (en) *	1993-07-16	1999-09-07	Schering Aktiengesellschaft	Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5599809A (en) *	1994-09-29	1997-02-04	Merck & Co., Inc.	Method for improving reproductive efficiency in farm animals
US20010056068A1 (en) *	1998-03-04	2001-12-27	Kristof Chwalisz	Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
FR2807038B1 (fr) *	2000-04-03	2002-08-16	Sanofi Synthelabo	Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant

2006
- 2006-05-10 CA CA2605923A patent/CA2605923C/en not_active Expired - Fee Related
- 2006-05-10 WO PCT/PL2006/000029 patent/WO2006121362A2/en not_active Ceased
- 2006-05-10 RU RU2007140702/15A patent/RU2385735C2/ru active
- 2006-05-10 ES ES06747719T patent/ES2366130T3/es active Active
- 2006-05-10 JP JP2008511075A patent/JP4762308B2/ja not_active Expired - Fee Related
- 2006-05-10 AU AU2006244693A patent/AU2006244693B2/en not_active Ceased
- 2006-05-10 AT AT06747719T patent/ATE507830T1/de active
- 2006-05-10 CN CN2006800568367A patent/CN101646436B/zh not_active Expired - Fee Related
- 2006-05-10 KR KR1020077025706A patent/KR100985449B1/ko not_active Expired - Fee Related
- 2006-05-10 NZ NZ562409A patent/NZ562409A/en not_active IP Right Cessation
- 2006-05-10 EP EP06747719A patent/EP1879572B1/de active Active
- 2006-05-10 DE DE602006021736T patent/DE602006021736D1/de active Active
- 2006-05-10 MX MX2007014022A patent/MX2007014022A/es active IP Right Grant
- 2006-05-10 SI SI200631039T patent/SI1879572T1/sl unknown
- 2006-05-10 US US11/914,049 patent/US20080318847A1/en not_active Abandoned
- 2006-05-10 PL PL06747719T patent/PL1879572T3/pl unknown
- 2006-05-10 DK DK06747719.0T patent/DK1879572T3/da active
- 2006-05-10 PT PT06747719T patent/PT1879572E/pt unknown
2007
- 2007-10-11 IL IL186595A patent/IL186595A/en active IP Right Grant
- 2007-12-10 NO NO20076328A patent/NO340956B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2605923C (en)	2012-07-24
US20080318847A1 (en)	2008-12-25
KR100985449B1 (ko)	2010-10-05
RU2007140702A (ru)	2009-06-20
NO20076328L (no)	2007-12-10
EP1879572B1 (de)	2011-05-04
JP2008540519A (ja)	2008-11-20
IL186595A0 (en)	2008-01-20
EP1879572A2 (de)	2008-01-23
RU2385735C2 (ru)	2010-04-10
CN101646436A (zh)	2010-02-10
KR20070118186A (ko)	2007-12-13
CN101646436B (zh)	2012-07-18
NO340956B1 (no)	2017-07-31
CA2605923A1 (en)	2006-11-16
SI1879572T1 (sl)	2011-07-29
DK1879572T3 (da)	2011-07-04
ES2366130T3 (es)	2011-10-17
NZ562409A (en)	2011-02-25
WO2006121362A3 (en)	2007-05-03
JP4762308B2 (ja)	2011-08-31
PT1879572E (pt)	2011-08-23
IL186595A (en)	2013-10-31
MX2007014022A (es)	2008-02-07
AU2006244693B2 (en)	2010-11-04
WO2006121362A2 (en)	2006-11-16
PL1879572T3 (pl)	2011-10-31
DE602006021736D1 (de)	2011-06-16
AU2006244693A1 (en)	2006-11-16

Legal Events

Date

Code

Title

Description

2011-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1879572

Country of ref document: EP

Publication	Publication Date	Title
IL186595A0 (en)	2008-01-20	Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
MX2021002322A (es)	2021-04-28	Nuevos metodos.
CO2020015256A2 (es)	2020-12-21	Compuestos y métodos para la reducción de la expresión de lrrk2
JOP20200277B1 (ar)	2024-04-18	مركبات تثبيط rip1 وطرق لتحضير واستخدامها
CR20190311A (es)	2019-08-20	Composiciones para tratar afecciones inflamatorias
PA8780101A1 (es)	2008-12-18	Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
BR112012004453A8 (pt)	2021-06-08	composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
CO6290684A2 (es)	2011-06-20	Inhibidores de actividad de proteina tirosina quinasa
MX2009009146A (es)	2009-09-03	Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus.
BR112015001419A8 (pt)	2019-07-30	composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
CR10309A (es)	2008-12-03	"compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP045474A (es)	2005-01-28	1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
BR112015023412A8 (pt)	2018-01-23	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
CL2008002138A1 (es)	2009-10-23	Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células.
EA201892286A1 (ru)	2019-04-30	Лекарственные формы с модифицированным высвобождением для снижения злоупотреблений
BR112015028613A2 (pt)	2017-07-25	análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
PH12020551911A1 (en)	2021-06-14	Use of riluzole oral disintigrating tablets for treating diseases
BR112019025578A2 (pt)	2020-06-16	Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas
MX2024013184A (es)	2024-12-06	Metodos y composiciones para tratar apnea del sue?o
MX2010010799A (es)	2011-03-25	Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
UY29995A1 (es)	2007-07-31	Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
CL2008003362A1 (es)	2009-06-26	Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje.
UY33529A (es)	2012-02-29	Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112018073419A2 (pt)	2019-03-19	combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112022009716A2 (pt)	2022-08-09	Dosagem de um inibidor de tirosina quinase de bruton